Quantcast

Industry news that matters to you.  Learn more

CompanDx Launches Biomarker Panel for Predicting Time to Breast Cancer Metastasis

U.K.-based biomarker discovery services firm Compandia has changed its name to CompanDx and launched a 31 gene breast cancer metastasis prediction panel it calls Time to an Event. Developed using the company’s Risk Distiller bioinformatics tool, the Time to an Event biomarker panel can accurately predict time to metastasis following initial surgery and biopsy, CompanDx claims. The firm says it is now applying for funding to further validate the panel in the clinic. It already has collaborations in place with leading clinical centers, and industry support has been secured with a major diagnostics company.

Study: PET Biomarker Gets Validation for Alzheimer’s Disease

18F-Flutemetamol performs similarly to the 11C-Pittsburgh compound B (11C-PIB) parent molecule within the same subjects and provides high test-retest replicability and potentially much wider accessibility for clinical and research use for Alzheimer’s disease, based on a study in the September issue of the Annals of Neurology.

Ariana Pharma Collaborates with the FDA to Facilitate Signature Validation for the Development of Biomarkers

Ariana Pharma, a leader in decision support tools and services to accelerate the development and optimal use of drugs and biomarker discovery, announces today that it has started a collaboration with the US Food and Drug Administration (FDA). Ariana Pharma is providing its KEM® Biomarker technology to help enable FDA reviewers to analyze pharmacogenomic data combined with patient characteristics for biomarker signatures submitted through the FDA’s Voluntary Exploratory Data Submission (VXDS) program. This collaboration directly relates to the FDA’s desire to develop better tools for the analysis of genomic data in the context of the development of personalized medicine.

Immunogenicity Testing Proves Invaluable

Immunogenicity is a measure of the immune response to a biotherapeutic drug. It is a very relevant issue affecting not only the use of therapeutic protein drugs such as mAbs but also peptides, enzymes, cytokines, growth factors, recombinant proteins, and other biological products.

GeneNews Expected to Debut ColonSentry in New York by Year’s End

GeneNews is expected to debut in its ColonSentry colorectal cancer screening LDT in New York State either by the end of the year or within the first three months of 2011, according to an equities analyst.

Reni Benjamin of Rodman & Renshaw on Tuesday said GeneNews’s R&D partner Enzo Biochem’s clinical lab division has finished validating the PCR-based test, and is about to submit the final data package to state regulators.